Patents Examined by Alana Harris Dent
  • Serum markers associated with early and other stages of breast cancer
    Patent number: 9140704
    Abstract: Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: September 22, 2015
    Assignee: Temple University of The Commonwealth System of Higher Education
    Inventors: Frank N. Chang, Phu T. Duong, George P. Tuszynski
  • RAB6KIFL/KIF20A epitope peptide and vaccines containing the same
    Patent number: 9132176
    Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 15, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Katsunori Imai, Yusuke Nakamura, Takuya Tsunoda
  • Diagnosis or prognosis of lung cancer and colorectal cancer based on expression level of glutaredoxin 3
    Patent number: 9128095
    Abstract: The present invention relates to a biomarker for diagnosing lung cancer and colorectal cancer containing glutaredoxin 3 as an active ingredient, and a kit for diagnosing lung cancer and colorectal cancer using the same biomarker. Glutaredoxin 3 of the present invention is over-expressed in lung cancer tissue and colorectal cancer tissue, which enables early prediction of diagnosis or prognosis of lung cancer and colorectal cancer. Thus, glutaredoxin 3 can be helpfully used as a biomarker for diagnosing lung cancer and colorectal cancer.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: September 8, 2015
    Assignee: PAICHI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventor: Il Han Kim
  • Detection of histone modification in cell-free nucleosomes
    Patent number: 9128086
    Abstract: This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the analysis of cell-free nucleosomes in samples from individuals. Methods of the invention may include contacting cell-free nucleosomes from a biological fluid sample obtained from the individual with an antibody that binds specifically with a modified histone protein. Binding of the antibody to the nucleosomes is indicative that the individual has the disease condition.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: September 8, 2015
    Assignee: SINGAPORE VOLITION PTE. LIMITED
    Inventors: Lindsay Jane Bawden, Elizabeth Ann Bone, Alan Hastings Drummond, Lindsey Ann Needham
  • Compositions and methods of identifying tumor specific neoantigens
    Patent number: 9115402
    Abstract: The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: August 25, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu
  • Antibodies of the ED-B domain of fibronectin, their construction and uses
    Patent number: 9096670
    Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: August 4, 2015
    Assignee: PHILOGEN S.P.A.
    Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
  • Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
    Patent number: 9090693
    Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies. Methods for treatment of cancer and reduction of tumor growth in individuals with secondary EGFR mutations, particularly tyrosine kinase domain mutations, resistant to standard therapy are provided. The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies. Methods for treatment of recurrent lung cancer, including non-small cell lung carcinoma which is resistant to tyrosine kinase inhibitors, with the antibody anti-EGFR mAb806 are described.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: July 28, 2015
    Assignee: Dana-Farber Cancer Institute
    Inventor: Kwok-Kin Wong
  • Prostate carcinogenesis predictor
    Patent number: 9078915
    Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: July 14, 2015
    Assignees: University of South Florida, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Mildred Enid Acevedo-Duncan, Hla Y. Win, Raoul Salup
  • Method for treating ocular cancer
    Patent number: 9078895
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: July 14, 2015
    Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical Center
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Methods and products for treating proliferative diseases
    Patent number: 9073985
    Abstract: Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-D-glucose and anti-VEGF antibodies. The systems and methods of the invention may be used to treat drug-resistant or multi-drug resistant cancers.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: July 7, 2015
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Martha Karen Newell, Susannah K. Rogers
  • Genetic products differentially expressed in tumors and the use thereof
    Patent number: 9044382
    Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: June 2, 2015
    Assignee: Ganymed Pharmaceuticals AG
    Inventors: Özlem Türeci, Ugur Sahin, Michael Koslowski, Stefan Fritz, Harald-Gerhard Geppert
  • ADAM-15 antibodies and immunogenic peptides
    Patent number: 9040049
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: May 26, 2015
    Assignee: Vasgen Limited
    Inventors: Salman Rahman, Yatin Patel, Holger Gerhardt, Andrea Emma Lundkvist
  • G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
    Patent number: 8980269
    Abstract: A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 17, 2015
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Frank N. Chang, George P. Tuszynski
  • Use of IMP3 as a prognostic marker for cancer
    Patent number: 8980638
    Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: March 17, 2015
    Assignee: University of Massachusetts
    Inventor: Zhong Jiang
  • Method for cancer detection
    Patent number: 8975030
    Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 10, 2015
    Assignees: Tsinghua University, Protgen Ltd.
    Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
  • Internalizing erbB2 antibodies
    Patent number: 8974792
    Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: March 10, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Marie Alix Poul
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8951744
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 10, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • SPARC and methods of use thereof
    Patent number: 8946169
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: February 3, 2015
    Assignee: NantBioScience, Inc.
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Methods of renal cell carcinoma prognosis and treatment selection with carbonic anhydrase IX
    Patent number: 8936914
    Abstract: The present invention provides methods of aiding in a renal cell carcinoma prognosis that include quantifying expressed carbonic anhydrase in samples derived from renal cell carcinoma patients. The methods also identify patients that are likely to respond positively to selected courses of treatment. The invention further provides related computer program products.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: January 20, 2015
    Assignee: The Regents of the University of California
    Inventors: Matthew H. T. Bui, David Seligson, Arie S. Belldegrun